Table 3.
Parameter changes between baseline and midterm in patients with conventional (CON) or reverse (REV) NAC. A stronger decrease of some parameters was observed in patients undergoing four cycles of NAC containing epirubicin when compared to patients undergoing four cycles of docetaxel. M = midterm; B = baseline; N = number of patients, min = minimum; max = maximum
| Change between baseline and midterm (M-B) | |||||
|---|---|---|---|---|---|
| CON | REV | ||||
| Factor | N | Median | N | Median | p-value |
| (Min, Max) | (Min, Max) | ||||
| uPA | 39 | -79.9 (-1391.0, 2168.2) | 42 | 563.0 (-9843.9, 5260.4) | 0.0001 |
| CXCL10 (IP10) | 39 | -12.9 (-383.9, 26.2) | 41 | 17.7 (-93.8, 161.9) | 0.0001 |
| sTNFSF10 (sTRAIL) | 39 | -5.9 (-12,955.7, 95.9) | 41 | 3.4 (-1113.5, 94.8) | 0.0005 |
| suPAR | 39 | -381.1 (-4845.4, 2106.6) | 42 | 267.5 (-6872.9, 5487.1) | 0.0020 |
| CCL8 (MCP-2) | 39 | -9.3 (-71.1, 14.5) | 41 | 0.5 (-20.7, 32.4) | 0.0234 |
| CCL2 (MCP-1) | 39 | -17.4 (-196.8, 79.9) | 41 | 1.6 (-256.6, 157.8) | 0.0548 |
| sTIM-3 | 39 | -6.9 (-14,467.4, 2186.9) | 41 | 71.3 (-460.8, 681.8) | 0.0823 |
| sCD27 | 39 | -179.5 (-2115.8, 7743.4) | 41 | 22.9 (-3587.8, 3397.6) | 0.0893 |
| CSF-1 (M-CSF) | 39 | -2.5 (-22.6, 61.1) | 41 | 0.0 (-19.7, 14.0) | 0.1178 |
| sPD-L2 | 39 | -148.9 (-1145.6, 2076.9) | 41 | -57.8 (-1807.2, 1214.8) | 0.1224 |
| VEGF-A | 39 | 36.6 (-2937.2, 5025.5) | 41 | -8.9 (-228.8, 819.9) | 0.3681 |
| OPG | 39 | 0.0 (-441.7, 116.2) | 41 | -0.7 (-31.3, 29.6) | 0.3729 |
| sTNFSF12 (TWEAK) | 39 | -59.0 (-1449.4, 591.2) | 41 | -39.0 (-291.4, 608.0) | 0.4216 |
| CCL11 (Eotaxin-1) | 39 | -0.4 (-36.7, 45.6) | 41 | 4.9 (-138.1, 35.1) | 0.5097 |